Fundraising Fox

Arialys

La Jolla, US · Founded 2021 · Delaware corporation · 4 known investors

arialysrx.com ↗

Arialys Therapeutics develops precision medicines targeting pathogenic autoantibodies in the brain to treat neuropsychiatric disorders driven by autoimmune disease. The company focuses on blocking autoantibodies that target brain receptors like NMDA receptors, with initial applications in conditions including encephalitis, schizophrenia, and dementia.

BiotechDigital HealthMedical Devicesin /arialys-therapeutics-inc@ArialysRx

Founders & leadership

JL
Jay Lichter, Ph.D.Director
PF
Peter Flynn, Ph.D.Executive Officer, Director
BS
Brian Slingsby, M.D., Ph.D., M.P.H.Director
EH
Ed HurwitzDirector
AX
Ashish Xavier, Ph.D.Director
TR
Tighe ReardonExecutive Officer

Investors · 4

Avalon BioVenturesSan Diego
Catalys PacificTokyo
MPM BioImpactBoston · $1M – $15M
MPM Capital

Reported raises · per SEC filings

Form D private placements
▶$14.8MraisedJul 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay Lichter, Ph.D.Director
  • Peter Flynn, Ph.D.Executive Officer, Director
  • Brian Slingsby, M.D., Ph.D., M.P.H.Director
  • Ed HurwitzDirector
  • Ashish Xavier, Ph.D.Director
Offering amount
$24.8M
Amount sold
$14.8M
First sale
Jun 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.3MraisedDec 2022 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay Lichter, Ph.D.Executive Officer, Director
  • Ed HurwitzDirector
  • Brian Slingsby, M.D., Ph.D., M.P.H.Director
  • Tighe ReardonExecutive Officer
Offering amount
$55M
Amount sold
$14.3M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news